Animal Research Licensing UK: What ASPA Requires for In Vivo Peptide Studies (2026)

Quick answer: any UK laboratory using research peptides in live animal studies must operate under the Animals (Scientific Procedures) Act 1986 (ASPA), which requires three linked authorisations — an establishment licence for the premises, a personal licence for each individual carrying out procedures, and a project licence describing the specific programme of work — all issued and inspected by the Home Office. This guide explains how animal research licensing UK works in practice, where the 3Rs principle fits before any in vivo work begins, and what it means for institutions sourcing research peptides for licensed studies. Daxer Labs supplies all products strictly for laboratory research use — nothing here is guidance on administering peptides to animals or humans, and every institution remains responsible for its own regulatory compliance.

The Animals (Scientific Procedures) Act 1986: The Legal Framework

ASPA is the primary legislation governing the use of living animals in scientific procedures in Great Britain, reflecting standards that continue to apply in UK law. It covers any procedure carried out on a protected animal — broadly, any living vertebrate or cephalopod — that may cause pain, suffering, distress or lasting harm, including many types of in vivo pharmacological or peptide research. The Act is enforced by the Animals in Science Regulation Unit (ASRU) within the Home Office, which inspects licensed establishments and can suspend or revoke authorisations for non-compliance. This three-tier licensing structure is the backbone of animal research licensing UK institutions must navigate before any in vivo peptide work begins.

When Does In Vivo Peptide Research Require a Home Office Licence?

If a research programme involves administering a peptide compound to a live protected animal — for example in a preclinical pharmacology or tissue-repair study — that work almost always falls within scope of ASPA and requires the full three-licence structure before any procedure takes place. In vitro work, such as cell-culture or tissue-sample assays using research peptides, sits outside ASPA entirely, which is one reason many institutions structure early-stage research to answer as many questions as possible in vitro before any project licence application is considered.

The Three Licence Types: Establishment, Personal & Project Licences

• Establishment licence — held by the institution itself, confirming its facilities, named veterinary surgeon, and named animal care and welfare officer meet Home Office standards

• Personal licence — held by each individual who will personally carry out regulated procedures, following approved training and a competency assessment

• Project licence — describes the specific programme of work, its scientific justification, and the numbers and species of animals involved, and must be approved before any procedure under it begins

All three must be in place and current before a single procedure is carried out. A valid establishment licence does not authorise an individual to act without their own personal licence, and neither authorises work outside an approved project licence.

The 3Rs Principle: Replacement, Reduction, Refinement

Every ASPA project licence application must demonstrate how the proposed work applies the 3Rs: Replacement of animal use with non-animal methods wherever possible, Reduction of the number of animals used to the minimum needed for statistically valid results, and Refinement of procedures to minimise pain, suffering and distress. The National Centre for the 3Rs (NC3Rs) publishes guidance and funds research aimed specifically at reducing reliance on in vivo models, and Home Office reviewers expect applicants to show they have genuinely considered in vitro or computational alternatives before requesting animal use.

In Vitro Alternatives: Where They Fit Before Animal Studies

Many peptide research questions — binding behaviour, stability, purity confirmation, cell-level activity — can be answered using in vitro methods such as HPLC analysis, mass spectrometry, and cell-culture assays, all of which sit entirely outside ASPA’s scope. Structuring a research programme so that as much groundwork as possible happens in vitro, with animal studies reserved for questions that genuinely cannot be answered any other way, is both a Home Office expectation under the 3Rs and, in practice, the more common route by which institutions satisfy their Replacement obligation.

What This Means for Sourcing Research Peptides

Licensing under ASPA governs how a peptide is used once it reaches a licensed facility — it does not change the compliant, research-use-only basis on which the peptide itself is bought and sold. Institutions running licensed in vivo work still need the same underlying assurance as any other research buyer: a batch-specific Certificate of Analysis confirming identity and purity, traceable documentation, and a supplier that markets strictly to laboratories rather than end consumers. For any institution navigating animal research licensing UK requirements, peptide sourcing compliance runs alongside, not in place of, ASPA authorisation.

Animal Research Licensing UK: Key Compliance Checkpoints

• Confirm the establishment holds a current Home Office establishment licence before any in vivo work is planned

• Verify that every individual carrying out procedures holds a personal licence covering that specific technique

• Ensure the intended work is described within an approved project licence before it begins

• Document how the 3Rs — particularly Replacement with in vitro methods — were considered at the application stage

• Retain batch-specific Certificates of Analysis for every research peptide used in a licensed project

• Keep records ready for ASRU inspection at any point

Frequently Asked Questions

Does ASPA apply to in vitro peptide research?

No. The Animals (Scientific Procedures) Act 1986 only applies to regulated procedures carried out on living protected animals. Cell-culture, tissue-sample and other in vitro peptide research sits outside its scope entirely.

Who enforces animal research licensing in the UK?

The Animals in Science Regulation Unit (ASRU), part of the Home Office, issues establishment, personal and project licences and carries out inspections to confirm compliance with ASPA.

Can an individual researcher hold a personal licence without their institution holding an establishment licence?

No. Establishment, personal and project licences must all be in place together. A personal licence only authorises work carried out at a currently licensed establishment under an approved project licence.

What are the 3Rs in animal research licensing?

Replacement, Reduction and Refinement — the principle that animal use should be replaced with non-animal methods wherever possible, reduced to the minimum necessary, and refined to minimise suffering. Every ASPA project licence application must address it.

Does Daxer Labs supply peptides for licensed animal research?

Daxer Labs supplies research peptides strictly for laboratory research use, including to institutions running ASPA-licensed in vivo programmes, with a batch-specific Certificate of Analysis on every order. Compliance with ASPA licensing itself remains the responsibility of the researching institution.

Research Use Only Disclaimer

This article is a general explainer of the ASPA licensing framework and is not legal or regulatory advice. It does not constitute guidance on administering research peptides to animals or humans, and any institution planning in vivo research must obtain its own establishment, personal and project licences from the Home Office before any procedure begins. All Daxer Labs peptides are sold strictly for research and analytical purposes only.

Source Research Peptides for Licensed Laboratory Programmes

Institutions running licensed research programmes need documentation they can rely on. BPC157/TB500 ships with a full, chromatogram-verified Certificate of Analysis, giving your establishment a traceable reference point for every batch used within an approved project licence.